CAR-T cell therapy
After CAR-T cells are cultured to a certain number, they are then infused back into the bloodstream of cancer patients, where they return to the body to perform the work of eliminating cancer cells. (Picture 1)
It is conceivable that every step of the preparation process of CAR-T cells needs to rely on small molecules on the cell surface to screen and monitor the cell status. It is often used in the development of therapeutics to screen and isolate T cells from complex blood samples. The specific antibody with fluorescence is used to bind to the antigen of the relevant T CELL, and then the fluorescence signal is interpreted by FC to show the information of the ratio of different immune cell types. CD33, CD64, etc. (indicator expression in B-ALL patients: CD3-CD14-CD64-CD33loCD19+), T CELL includes CD3, CD4, CD8, etc. In addition, after the CAR-T is reinfused into the human body, the proportion of immune cell subsets also needs to be detected to evaluate the therapeutic effect. For example, by FC analysis of the distribution of immune cell subsets in B-ALL patients before and after CAR-T treatment, it can be seen that the amount of CD3-CD19+ B cells will increase significantly, indicating that CAR-T immunotherapy has a certain effect. Proteintech has a complete FC antibody product for T cell surface antigens, 100% FC-validated, providing the most efficient T cell sorting solution!
When T cells are successfully isolated, the next step is to stimulate activation and expansion of T cells. Common tools for in vitro activation of T cells include anti-CD3, CD28 antibodies, cytokines IL-2, IL-7, IL-23, IL-15, IL-21, etc. According to Gargett et al., the co-culture of CD3/CD28 with cytokines IL-4 and IL-15 helps to obtain CAR-T cells with better expansion and durability. The Humankine series of proteins developed by Proteintech’s exclusive technology have a variety of essential cytokines for Car-T cell culture. According to GMP production specifications, they are the best choice for clinical use!
When the CAR-T cell is successfully constructed and reinfused into the living body, it is necessary to arrange experimental animals to evaluate the titer of the CAR-T cell, including the detection of inflammatory factors and target cell subsets. Cytokine concentrations in the serum of transfused patients were monitored to prevent the occurrence of cytokine storms. Among them, inflammation-related cytokines and chemokines such as IL-2, TNF-α, IFN-γ, IL-6, IL-7, IL-8, IL-10, IL-12, sIL-2Ra, etc. A reported subject of surveillance (Xu and Tang, 2014). Proteintech provides a variety of highly sensitive ELISA kits developed with Humankine, which is the closest to the real human target protein, as the antigen, which truly reflects the status of CAR-T cells:
Lung Restoration and Strengthening Ver 2.0 (Morphic Field) - YouTube
